Treprostinil

• CAT Number: R051422
• CAS Number: 81846-19-7
• Molecular Formula: C23H34O5
• Molecular Weight: 390.5
• Purity: 98%
• Synonyms: Remodulin; Uniprost.
• Storage: -20°C
• IUPAC Name: 2-[[(1R,2R,3aS,9aS)-2-hydroxy-1-[(3S)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[g]naphthalen-5-yl]oxy]acetic acid
• InChI: InChI=1S/C23H34O5/c1-2-3-4-7-17(24)9-10-18-19-11-15-6-5-8-22(28-14-23(26)27)20(15)12-16(19)13-21(18)25/h5-6,8,16-19,21,24-25H,2-4,7,9-14H2,1H3,(H,26,27)/t16-,17-,18+,19-,21+/m0/s1
• InChIKey: PAJMKGZZBBTTOY-ZFORQUDYSA-N
• SMILES: O=C(O)COC1=C(C[C@](C[C@@H](O)[C@@H]2CC[C@@H](O)CCCCC)([H])[C@]2([H])C3)C3=CC=C1

Treprostinil is a synthetic analogue of prostacyclin (PGI2), used primarily in the treatment of pulmonary arterial hypertension (PAH). It works by dilating blood vessels in the lungs, reducing blood pressure, and improving oxygen delivery, thereby enhancing exercise capacity and reducing symptoms in patients with PAH. Treprostinil also inhibits platelet aggregation and smooth muscle proliferation, contributing to its therapeutic effects. It can be administered via various routes, including subcutaneous, intravenous, oral, and inhaled formulations, offering flexibility in treatment. Due to its vasodilatory and anti-proliferative properties, Treprostinil is a key medication in the management of PAH to improve quality of life.